Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU OKs Merck/Schering deal

This article was originally published in The Tan Sheet

Executive Summary

The European Commission Oct. 23 approves the pending Merck/Schering-Plough merger, and the firms say they expect the transaction to close this year. During Merck's fiscal 2009 third-quarter earnings call Oct. 22, Merck President and CEO Richard Clark told analysts the firm's OTC joint venture with Johnson & Johnson, which covers U.S. and Canadian business, will remain separate from the Merck/Schering business, but he declined to say whether possible switches of Schering's existing OTC products would have to go through the joint venture. Pending U.S. regulatory approval, Merck will purchase S-P for $41.1 billion (1"The Tan Sheet" March 16, 2009). ... Schering consumer sales flat: MiraLAX sales nearly doubled in the third quarter to $31 million and the laxative is "running neck and neck" with Procter & Gamble's Metamucil, Schering CFO Robert Bertolini says Oct. 22. But the consumer health care business grew only 2 percent to $282 million, hampered by lower sales of OTC Claritin (down 7 percent), sun care (down 19 percent) and foot care (down 5 percent), the Kenilworth, N.J., firm said. Net sales in the July-September period dipped 2 percent to $4.5 billion, and net income fell 17 percent to $477 million

You may also be interested in...

Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights

Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts